Compare ROP & IQV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ROP | IQV |
|---|---|---|
| Founded | 1981 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.9B | 41.3B |
| IPO Year | 1992 | 2013 |
| Metric | ROP | IQV |
|---|---|---|
| Price | $350.56 | $182.16 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 15 |
| Target Price | ★ $495.43 | $242.60 |
| AVG Volume (30 Days) | ★ 2.0M | 1.6M |
| Earning Date | 01-27-2026 | 02-05-2026 |
| Dividend Yield | ★ 1.04% | N/A |
| EPS Growth | N/A | ★ 4.67 |
| EPS | ★ 14.20 | 7.84 |
| Revenue | $7,902,500,000.00 | ★ $16,310,000,000.00 |
| Revenue This Year | $8.94 | $6.14 |
| Revenue Next Year | $6.73 | $5.44 |
| P/E Ratio | $24.72 | ★ $23.08 |
| Revenue Growth | ★ 12.26 | 5.88 |
| 52 Week Low | $343.92 | $134.65 |
| 52 Week High | $595.17 | $247.05 |
| Indicator | ROP | IQV |
|---|---|---|
| Relative Strength Index (RSI) | 28.19 | 20.44 |
| Support Level | $343.92 | $176.07 |
| Resistance Level | $365.21 | $233.48 |
| Average True Range (ATR) | 12.46 | 9.36 |
| MACD | -3.09 | -6.94 |
| Stochastic Oscillator | 15.02 | 10.24 |
Roper Technologies is a holding company focused on acquiring, managing, and developing niche market-leading technology businesses. The company operates a decentralized business model whereby each portfolio company operates independently from the others. Roper positions itself as a free cash flow compounder, whereby excess free cash flow generated by its portfolio businesses is repatriated to the parent company, which is then utilized to acquire additional businesses. Presently, the company operates 30 distinct businesses with over three-fourths of the revenue coming from software products and over two-thirds of revenue coming from recurring and reoccurring sources.
Iqvia is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.